Drug intelligence / Profile preview

BDLenti-Solid Tumor

Development stage: Preclinical
Lead developer: Shanghai BDgene Therapeutics
Modality: Gene Therapies
Administration: Intratumoral

Overview

BDLenti-Solid Tumor is a preclinical gene therapy candidate developed by Shanghai BDgene Therapeutics for the treatment of solid tumors. The program utilizes the proprietary BDlenti platform, which is a lentiviral vector-based system designed for gene addition. While the specific molecular target and transgene delivered by the vector have not been publicly disclosed, the therapy is engineered to introduce therapeutic genetic material into cells to address solid malignancies. The project is currently in the preclinical stage of development.

Beyond the preview

Go deeper on BDLenti-Solid Tumor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDLenti-Solid Tumor.

Explore the full profile